Roivant Sciences Ltd. $ROIV Stock Acquired by Yousif Capital Management LLC

Yousif Capital Management LLC lifted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 12.4% in the third quarter, HoldingsChannel.com reports. The fund owned 146,000 shares of the company’s stock after buying an additional 16,164 shares during the quarter. Yousif Capital Management LLC’s holdings in Roivant Sciences were worth $5,339,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ROIV. Assenagon Asset Management S.A. grew its holdings in Roivant Sciences by 18.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock valued at $295,965,000 after buying an additional 1,286,464 shares in the last quarter. Perceptive Advisors LLC grew its stake in Roivant Sciences by 3.8% during the first quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company’s stock valued at $229,507,000 after acquiring an additional 300,000 shares in the last quarter. Bank of America Corp DE grew its position in shares of Roivant Sciences by 8.0% during the first quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock valued at $87,638,000 after purchasing an additional 235,493 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Roivant Sciences by 6.1% during the 1st quarter. Janus Henderson Group PLC now owns 3,095,448 shares of the company’s stock valued at $85,790,000 after buying an additional 177,339 shares in the last quarter. Finally, Jennison Associates LLC increased its stake in Roivant Sciences by 26.7% in the 1st quarter. Jennison Associates LLC now owns 2,982,799 shares of the company’s stock worth $82,624,000 after acquiring an additional 629,413 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Shares of ROIV opened at $36.49 on Monday. The stock has a market capitalization of $26.36 billion, a PE ratio of -68.85 and a beta of 1.10. The company has a 50 day moving average price of $36.62 and a 200-day moving average price of $33.38. Roivant Sciences Ltd. has a fifty-two week low of $17.89 and a fifty-two week high of $42.50.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Equities research analysts forecast that Roivant Sciences Ltd. will post -2.00 EPS for the current year.

Insider Buying and Selling

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 20th. The shares were sold at an average price of $35.11, for a total transaction of $7,022,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,399,154 shares of the company’s stock, valued at approximately $49,124,296.94. This trade represents a 12.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa B. Epperly sold 17,750 shares of Roivant Sciences stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $36.10, for a total transaction of $640,775.00. Following the sale, the director owned 14,954 shares of the company’s stock, valued at approximately $539,839.40. The trade was a 54.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,622,688 shares of company stock valued at $58,858,636 over the last quarter. 8.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ROIV has been the topic of several research reports. HC Wainwright boosted their price target on shares of Roivant Sciences from $41.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Roivant Sciences in a report on Wednesday, August 19th. Guggenheim lifted their price target on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Finally, Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $45.64.

Roivant Sciences Profile

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.